ADMA NASDAQ
ADMA Biologics, Inc.
1W: -0.5%
1M: +10.4%
3M: +28.2%
YTD: -37.5%
1Y: -26.4%
3Y: +253.5%
5Y: +906.3%
$11.17
+0.10 (+0.95%)
Pre-Market: $10.95 (-0.22, -2.01%)
Weekly Expected Move ±5.8%
$9
$10
$11
$11
$12
Credit Risk of going bust: lower than 58% of companies Debt: 7.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.10 (down 99.1%), ADMA Biologics, Inc. would be worth roughly what it owes.
Total debt $203.8M against a stock market value of $2.50B.
Distance to default 5.92 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $100.2M (short-term plus half of long-term), stock volatility 55.4%; Altman Z'' 7.73. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.10 (down 99.1%), ADMA Biologics, Inc. would be worth roughly what it owes.
Total debt $203.8M against a stock market value of $2.50B.
Distance to default 5.92 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $100.2M (short-term plus half of long-term), stock volatility 55.4%; Altman Z'' 7.73. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (24h)
1
Hourly Sentiment (24h)
Articles (1)
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
Oppenheimer's top 50 small- and mid-cap Sell ideas
Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?
Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors
ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Know
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market
Bank of America Corp DE Makes New $13.79 Million Investment in ADMA Biologics Inc $ADMA
Why Adma Biologics (ADMA) Dipped More Than Broader Market Today
Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?
Corient Private Wealth LP Buys 254,124 Shares of ADMA Biologics Inc $ADMA
Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
Adma Biologics (ADMA) Falls More Steeply Than Broader Market: What Investors Need to Know
Ten healthcare stocks with A-rated valuations and strong revenue growth
Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?
Adma Biologics (ADMA) Down 4.8% Since Last Earnings Report: Can It Rebound?
Bank of New York Mellon Corp Takes Position in ADMA Biologics Inc $ADMA
Bank of America Corp DE Raises Holdings in ADMA Biologics Inc $ADMA
Can Asceniv Help ADMA Stock Combat IG Market Challenges?
ADMA DEADLINE TOMORROW: ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action First Filed by the Firm – ADMA
ADMA Biologics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ADMA Biologics, Inc. - ADMA
ADMA Q2 Earnings Meet, Revenues Miss on Bivigam Weakness
ADMA reiterates 2026 guidance of $530M-$560M revenue while targeting $200M+ in share repurchases
Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note
Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note
Wall Street Analysts See Adma Biologics (ADMA) as a Buy: Should You Invest?
Adma Biologics (ADMA) Rises Higher Than Market: Key Facts
Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note
Important Notice to Long-Term Shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA); Commvault Systems, Inc. (NASDAQ: CVLT); Erasca, Inc. (NASDAQ: ERAS); and Hub Group, Inc. (NASDAQ: HUBG): Grabar Law Office is Investigating Claims on Your Behalf
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 10, 2026 in ADMA BIOLOGICS, INC. Lawsuit - ADMA
Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights
Levi & Korsinsky Reminds ADMA BIOLOGICS, INC. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 10, 2026 - ADMA
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell?
Is ADMA Stock's 13.5% Monthly Gain a Sign of Recovery?
ADMA BIOLOGICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ADMA Biologics, Inc. and Encourages Investors to Contact the Firm
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against BitGo Holdings, Inc. (BTGO), ADMA Biologics, Inc. (ADMA), and Erasca, Inc. (ERAS) Announced by Holzer & Holzer, LLC
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could
$ADMA Stock News: ADMA Biologics Stock Dropped 29% after Channel Stuffing Allegations – Investors Notified to Contact BFA Law about the Securities Class Action Lawsuit
Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors
Adma Biologics (ADMA) Dips More Than Broader Market: What You Should Know
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
INVESTOR NOTICE: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against ADMA Biologics, Inc. (ADMA), Erasca, Inc. (ERAS), and Nano-X Imaging Ltd. (NNOX) Announced by Holzer & Holzer, LLC
ADMA Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the ADMA Biologics, Inc. Class Action Lawsuit
Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
ADMA INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
ADMA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ADMA Biologics, Inc. and Encourages Investors to Contact the Firm
Adma Biologics (ADMA) Stock Dips While Market Gains: Key Facts
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against ADMA Biologics, Inc. (ADMA)
ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA
ADMA LAWSUIT: ADMA Biologics, Inc. Sued For Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses
Adma Biologics (ADMA) Down 5.8% Since Last Earnings Report: Can It Rebound?
New Strong Sell Stocks for June 3rd
ADMA Legal Claims: ADMA Biologics may have Misrepresented its Revenue Sources to Investors – Contact BFA Law about its Pending Securities Fraud Investigation
Is ADMA Biologics, Inc. (ADMA) Among the Best Russell 2000 Stocks to Invest In According to Hedge Funds? - Yahoo Finance
ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
Can Asceniv Help ADMA Navigate the Current IG Market Challenges?
New Strong Sell Stocks for May 26th
$ADMA Shareholder Announcement: ADMA Biologics may have Misled Investors about its Revenue – Contact BFA Law about its Pending Investigation
Lowey Dannenberg, P.C. is Investigating ADMA Biologics (NASDAQ: ADMA) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the Firm
Will the IG Market Challenges Affect ADMA Biologics Prospects in 2026?
Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year
ADMA Securities Investigation: ADMA Biologics 29% Stock Drop Triggers Securities Fraud Investigation Over Channel Stuffing Claims – Investors Urged to Contact BFA Law
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
Is it Time to Exit ADMA Biologics Stock After a 22% Monthly Plunge?
ADMA Fraud Notice: ADMA Biologics is being Investigated for Securities Fraud after 29% Stock Drop -- Investors Reminded to Contact BFA Law
ADMA Shareholder News: ADMA Biologics Investigated for Securities Fraud Over Alleged Misrepresentations about Channel Stuffing – Investors Notified to Contact BFA Law
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?
New Strong Sell Stocks for May 14th
$ADMA Investigation Reminder: ADMA Biologics Investigation on behalf of Investors is Ongoing – Contact BFA Law if You Lost Money
New Strong Sell Stocks for May 11th
Lowey Dannenberg, P.C. is Investigating ADMA Biologics (NASDAQ: ADMA) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the Firm
$ADMA Investor News: ADMA Biologics Stock Drops 29% Amid Channel Stuffing Claims Triggering Securities Fraud Investigation – Contact BFA Law if You Suffered Losses
ADMA Q1 EPS Jumps 73% Y/Y, Revenues Slip, 2026 View Down
ADMA Biologics declines 17% after lowering FY26 outlook, withdrawing long-term guidance
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Snap, Whirlpool, Nerdwallet And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Adma projects 2026 revenue of $530M-$560M and withdraws longer-term guidance amid standard IG dislocation
BREAKING: ADMA Biologics Shares Fall Over 24%; Investors Encouraged to Contact Block & Leviton to Possibly Recover Losses
ADMA (ADMA) Q1 2026 Earnings Transcript
12 Health Care Stocks Moving In Wednesday's After-Market Session
Earnings Scheduled For May 6, 2026
Here are the major earnings after the close Wednesday
$ADMA Shareholder News: ADMA Biologics 29% Stock Drop Leads to Securities Fraud Investigation – BFA Law Encourages Investors with Losses to Act
Will the Label Expansion of Asceniv Boost ADMA's Top-Line Growth?
$ADMA Stock Drop Alert: ADMA Biologics Stock Plummeted 29% on News of Channel Stuffing – Investors Notified to Contact BFA Law about its Investigation
ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Investor Notice: ADMA Biologics (NASDAQ:ADMA) may have Committed Securities Fraud after Channel Stuffing Claims Disclosed – Contact BFA Law about the Pending Investigation
Adma Biologics (ADMA) Dips More Than Broader Market: What You Should Know
Summers Value Fund adds TBPH, exits ADMA among Q1 moves
$ADMA Fraud: ADMA Biologics Channel Stuffing Claims Trigger Securities Investigation – Investors Alerted to Contact BFA Law
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
ADMA Stock: ADMA Biologics Securities Fraud Investigation is Ongoing – Investors with Losses Urged to Contact BFA Law